The value of medical treatments is an issue that has been actively debated in recent years and is not unique to oncology. In this Comment, we discuss why we pursue treatments which might have limited benefit from the point of view of three parties: the patient, the physician, and the pharmaceutical industry.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS
Journal of Cancer Research and Clinical Oncology Open Access 04 March 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Davis, C. et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. BMJ 359, j4530 (2017).
Weeks, J. C. et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N. Engl. J. Med. 367, 1616–1625 (2012).
Duric, V. M. et al. Patients’ preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann. Oncol. 16, 1786–1794 (2005).
Verma, A. A., Razak, F. & Detsky, A. S. Understanding choice: why physicians should learn prospect theory. JAMA 311, 571–572 (2014).
Duggan, K. T. et al. Use of word “unprecedented” in the media coverage of cancer drugs: do “unprecedented” drugs live up to the hype? J. Cancer Policy 14, 16–20 (2017).
Booth, C. M. & Eisenhauer, E. A. Progression-free survival: meaningful or simply measurable? J. Clin. Oncol. 30, 1030–1033 (2012).
Boutron, I. et al. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303, 2058–2064 (2010).
Del Paggio, J. C. et al. Do contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit? Ann. Oncol. 28, 157–162 (2016).
Tibau, A. et al. Magnitude of clinical benefit of cancer drugs approved by the US Food and Drug Administration. J. Natl Cancer Inst. 110, 486–492 (2018).
Del Paggio, J. C. et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol. 18, 887–894 (2017).
Acknowledgements
The authors gratefully acknowledge V. Chopra and I. Tannock for their helpful comments on an earlier draft of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors have no competing interests.
Rights and permissions
About this article
Cite this article
Booth, C.M., Detsky, A.S. Why patients receive treatments that are minimally effective?. Nat Rev Clin Oncol 16, 3–4 (2019). https://doi.org/10.1038/s41571-018-0101-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0101-4
This article is cited by
-
Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS
Journal of Cancer Research and Clinical Oncology (2024)
-
Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review
PharmacoEconomics (2021)